{"analyses":[{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.04","estimateComment":"Tamoxifen was the reference group in the estimation of the hazard ratio.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1","paramType":"Hazard Ratio (HR)","paramValue":"0.83","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.86","estimateComment":"Tamoxifen was the reference group in the estimation of the hazard ratio.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.68"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.2","upperLimit":"86.9","value":"84.7"},{"groupId":"OG001","lowerLimit":"84.2","upperLimit":"88.7","value":"86.6"},{"groupId":"OG002","lowerLimit":"86.8","upperLimit":"90.9","value":"89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1018"},{"groupId":"OG001","value":"1015"},{"groupId":"OG002","value":"1014"}],"units":"Participants"}],"description":"Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tamoxifen 20mg orally daily for 5 years","id":"OG000","title":"Tamoxifen"},{"description":"Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)","id":"OG001","title":"T+OFS"},{"description":"Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)","id":"OG002","title":"E+OFS"}],"paramType":"NUMBER","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"5-year estimates, reported at a median follow-up of 67 months.","title":"Disease-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}